Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

doi:10.3748/wjg.v16.i43.5518

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 43

This Article

(0)

(4597)

(23)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Gastroenterol. Nov 21, 2010; 16(43): 5518-5522
Published online Nov 21, 2010. doi: 10.3748/wjg.v16.i43.5518

Full Size Figure Download Figure

Figure 1 Serum α-fetoprotein level measured as related to the treatment history. Serum α-fetoprotein (AFP) level was trending up after sorafenib therapy but normalized after sirolimus was initiated. Events are outlined in the Figure. CT: Computed tomography; HCC: Hepatocellular carcinoma.

Citation: Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report. World J Gastroenterol 2010; 16(43): 5518-5522
URL: https://www.wjgnet.com/1007-9327/full/v16/i43/5518.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i43.5518

Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report. World J Gastroenterol 2010; 16(43): 5518-5522 [PMID: 21086573 DOI: 10.3748/wjg.v16.i43.5518]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.